Lok Sabha Question No. 3351 (UNSTARRED), answered on 2019-07-12
Subject: Shortage of Vaccines
Ministry: HEALTH AND FAMILY WELFARE
Asked by: Kuldeep Rai Sharma, Heena Vijaykumar Gavit, Subhash Ramrao Bhamre, Supriya Sadanand Sule, Amol Ramsing Kolhe, Sunil Dattatray Tatkare

## GOVERNMENT OF INDIA MINISTRY OF HEALTH AND FAMILY WELFARE DEPARTMENT OF HEALTH AND FAMILY WELFARE

LOK SABHA UNSTARRED QUESTION NO.3351 TH

TO BE ANSWERED ON 12 JULY, 2019

## SHORTAGE OF VACCINES

## 3351. SHRI KULDEEP RAI SHARMA:

DR. HEENA GAVIT: DR. SUBHASH RAMRAO BHAMRE: SHRIMATI SUPRIYA SULE: DR. AMOL RAMSING KOLHE: SHRI SUNIL DATTATRAY TATKARE:

Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

- (a) the number of the Government controlled units engaged in the production of vaccines along with the production of each unit during each of the last three years and the current year, vaccine and unit - wise;
- (b) whether there is any shortage of certain vaccines against the usual requirements under various health programmes including the Universal Immunisation Programme (UIP), if so, the details of the  demand  and  supply  during the  above  said  period  and  its  impact  on various  health programmes run by the Government;
- (c) the quantum and types of vaccines imported as well as purchased from pr ivate companies for various health programmes along with the funds spent for the purpose during the above said period, vaccine - wise;and
- (d) the steps taken/being taken by the Government to ensure adequate availability of all the vaccines for the UIP and alsotheir availability in market at affordable prices in the country?

## ANSWER THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE

(SHRI ASHWINI KUMAR CHOUBEY)

- (a) The details of production for vaccines for the last three years period and current  financial  year  in  respect  of  Vaccine  Institutes  under  the  Ministry namely Central Research Institute, Kasauli (Himachal Pradesh), BCG Vaccine Laboratory, Guindy (Tamil Nadu) and Pasteur Institute of India, Coonoor (Tamil Nadu) is given at Annexure-I.
- (b) No.

(c) The quantum and types of vaccines purchased from providers other than Government  for  Universal  Immunization  Programme,  Pulse  Polio  Programme along with funds spent during the last three years period and current financial year is given at Annexure-II.

(d) All necessary actions are initiated well in advance for ensuring availability of vaccines for Universal Immunization Programme at affordable prices.

--

## PRODUCTION OF VACCINES FOR THE LAST THREE YEARS PERIOD AND CURRENT FINANCIAL YEAR IN RESPECT OF INSTITUTES UNDER THE MINISTRY

## (A) Central Research Institute, Kasauli:

| Vaccine    |   2016-17 |   2017-18 | 2018-19      | 2019-20      |
|------------|-----------|-----------|--------------|--------------|
| TT (doses) |   6471910 |   1177050 | Discontinued | Discontinued |

## (B) BCG Vaccine Laboratory, Guindy:

| Vaccine   | Installed Capacity   | 2016-17   | 2017-18   | 2018-19   | 2019-20   |
|-----------|----------------------|-----------|-----------|-----------|-----------|
| BCG       | 800 lakh doses/annum | -         | -         | -         | -         |

## (C) Pasteur Institute of India, Coonoor:

| Vaccine   | Installed Capacity   | 2016-17   | 2017-18   | 2018-19   | 2019-20   |
|-----------|----------------------|-----------|-----------|-----------|-----------|
| DPT       | 600 lakh doses/annum | -         | -         | -         | -         |
| TT        | 550 lakh doses/annum | -         | -         | -         | -         |
| DT        | 150 lakh doses/annum | -         | -         | -         | -         |

CRI, Kasauli; BCG VL, Guindy and PII, Coonoor have achieved current Good Manufacturing  Practice  (cGMP)  compliance  and  are  at  different  stages  of vaccine production for supplying to the Universal Immunization Programme.

## QUANTUM AND TYPES OF VACCINES FROM PROVIDERS OTHER THAN GOVERNMENT ALONG WITH THE FUNDS SPENT FOR THE LAST THREE YEARS PERIOD AND CURRENT FINANCIAL YEAR

| Year      | Types of vaccine                | Doses in lakh   | Funds spent   |
|-----------|---------------------------------|-----------------|---------------|
| 2016 -17  | Pentavalent (10 doses per vial) | 874.8           | 454.65        |
| 2016 -17  | BOPV (RI) (20 doses per vial)   | 770.0           | 49.79         |
| 2016 -17  | Measles (5 doses per vial)      | 350.0           | 39.75         |
| 2016 -17  | BCG (10 doses per vial)         | 562.5           | 20.77         |
| 2016 -17  | Rotavirus (10 doses per vial)   | 150.0           | 106.44        |
| 2016 -17  | IPV vaccine (5 doses per vial)  | 60.0            | 54.81         |
| 2016 -17  | BOPV (Dec 2016 PP)              | 875.0           | 56.73         |
| 2017-18 ) | Pentavalent                     | 848.2           | 867.11        |
| 2017-18 ) | BCG                             | 562.5           | 22.29         |
| 2017-18 ) | Hep-B                           | 310.9           | 0.00          |
| 2017-18 ) | IPV                             | 160.0           | 110.28        |
| 2017-18 ) | bOPV (Routine)                  | 1406.6          | 79.09         |
| 2017-18 ) | Measles                         | 419.0           | 49.50         |
| 2017-18 ) | MR vaccine                      | 487.5           | 175.92        |
| 2017-18 ) | TT vaccine                      | 289.6           | 7.29          |
| 2017-18 ) | ROTA Virus                      | 198.5           | 129.87        |
| 2017-18 ) | JE                              | 2.5             | 1.71          |
|           | bOPV ( Pulse Polio) Pentavalent | 5850.0 140.0    | 265.14 12.03  |
|           | Rotavirus                       | 338.5           | 144.98        |
|           | BCG + BCG (Under Tolerance)     | 675.0           | 9.66          |
|           | Td                              | 1225.0          | 20.13         |
| 2018-19   | MR                              | 2768.0          | 739.53        |
|           | bOPV(RI)                        | 80.0            | 0.00          |
|           | Rotavirus (Addl.)               | 220.9           | 0.00          |
|           | JE Live (under tolerance)       | 225.4           | 0.00          |
|           | JE Live (under tolerance)       | 403.6           | 0.00          |
|           | bOPV(PP)                        | 865.4           | 33.30         |

| 2019-20   | Pentavalent      |   335.0 |   0 |
|-----------|------------------|---------|-----|
| 2019-20   | Rotavirus        |   300   |   0 |
| 2019-20   | bOPV(RI)         |   276   |   0 |
| 2019-20   | IPV              |   110   |   0 |
| 2019-20   | Rotavirus(Addl.) |   397.9 |   0 |
| 2019-20   | DPT              |   432   |   0 |
| 2019-20   | MR               |   752   |   0 |
| 2019-20   | BCG              |   225   |   0 |
| 2019-20   | JE               |   172.2 |   0 |
| 2019-20   | bOPV(PP) New     |   780   |   0 |